Drug class profile · refreshed daily from federal data

Neurokinin 3 Receptor Antagonist

1 molecule in this class, $70.1M combined CY2024 Part D spend across 99K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Neurokinin 3 Receptor Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class
1tracked in Part D
CY24 Part D spend
$70.1Mcombined across class
Total Rx claims
99K29K unique beneficiaries
Generic mfrs (active)
0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard
01
Fezolinetant
Brand: VEOZAH · 99K Part D claims (CY24) · 29K beneficiaries · First FDA approval:
Brand-only (no generics) 170 plans require PA
Low NADAC$18.59
Avg plan cost$18.59
Part D spend $70.1M spread, current vs floor
Class share
100%
of class CY24 spend
View profile →